Review Topical Sections

Galectin-1 and galectin-3 as key molecules for peripheral nerve degeneration and regeneration

  • Received: 17 May 2016 Accepted: 04 July 2016 Published: 25 January 2016
  • There is growing evidence that galectin-1 (GAL-1) and galectin-3 (GAL-3) are involved in the process of axonal regeneration after injury and the pathogenesis of peripheral neuropathies, but the precise roles of these galectins in the peripheral nervous system (PNS) remain unclear. In this paper, we summarized the distribution and possible functions of GAL-1 and GAL-3 in the PNS at mature stages under normal and pathological conditions. Predominant expression of GAL-1 and GAL-3 in isolectin B4 (IB4)-binding small non-peptidergic sensory neurons in dorsal root ganglia (DRG) accords with the involvement of these molecules in nociceptive and thermoceptive functions and GDNF-induced neurite outgrowth. Up-regulation of GAL-1 mRNA/protein in the neurons and Schwann cells upon peripheral nerve injury suggests its active participation in axonal regeneration; both GAL-1 in the reduced and oxidized forms appear to be key molecules for normal onset of Wallerian degeneration and subsequent neurite outgrowth, but the latter lacks lectin activity and may promote the process by stimulating macrophages rather than directly acting on neurons. GAL-3 deficient mice exhibited the acceleration in the process of Wallerian degeneration, but there is room for argument on its pathological roles in axonal regeneration. Up-regulation of GAL-3 protein in immortalized Schwann cells IFRS1 under diabetic conditions and its cytoprotective functions on the cells suggest that it may act as a factor against the progression of diabetic neuropathy, but further evidence is needed to support this idea. All these findings have shed light on both physiological and pathological roles of GAL-1 and GAL-3 in the PNS, and further evidence will be helpful to develop novel strategies for functional restoration after peripheral nerve injury and therapeutic efficacy against diabetic and other neuropathies.

    Citation: Shizuka Takaku, Naoko Niimi, Toshihiko Kadoya, Hideji Yako, Masami Tsukamoto, Kunihiko Sakumi, Yusaku Nakabeppu, Hidenori Horie, Kazunori Sango. Galectin-1 and galectin-3 as key molecules for peripheral nerve degeneration and regeneration[J]. AIMS Molecular Science, 2016, 3(3): 325-337. doi: 10.3934/molsci.2016.3.325

    Related Papers:

  • There is growing evidence that galectin-1 (GAL-1) and galectin-3 (GAL-3) are involved in the process of axonal regeneration after injury and the pathogenesis of peripheral neuropathies, but the precise roles of these galectins in the peripheral nervous system (PNS) remain unclear. In this paper, we summarized the distribution and possible functions of GAL-1 and GAL-3 in the PNS at mature stages under normal and pathological conditions. Predominant expression of GAL-1 and GAL-3 in isolectin B4 (IB4)-binding small non-peptidergic sensory neurons in dorsal root ganglia (DRG) accords with the involvement of these molecules in nociceptive and thermoceptive functions and GDNF-induced neurite outgrowth. Up-regulation of GAL-1 mRNA/protein in the neurons and Schwann cells upon peripheral nerve injury suggests its active participation in axonal regeneration; both GAL-1 in the reduced and oxidized forms appear to be key molecules for normal onset of Wallerian degeneration and subsequent neurite outgrowth, but the latter lacks lectin activity and may promote the process by stimulating macrophages rather than directly acting on neurons. GAL-3 deficient mice exhibited the acceleration in the process of Wallerian degeneration, but there is room for argument on its pathological roles in axonal regeneration. Up-regulation of GAL-3 protein in immortalized Schwann cells IFRS1 under diabetic conditions and its cytoprotective functions on the cells suggest that it may act as a factor against the progression of diabetic neuropathy, but further evidence is needed to support this idea. All these findings have shed light on both physiological and pathological roles of GAL-1 and GAL-3 in the PNS, and further evidence will be helpful to develop novel strategies for functional restoration after peripheral nerve injury and therapeutic efficacy against diabetic and other neuropathies.


    加载中
    [1] Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10: e17. doi: 10.1017/S1462399408000719
    [2] Sango K, Yanagisawa H, Watabe K, et al. (2012) Chapter 3: Galectin-1 as a multifunctional molecule in the peripheral nervous system after injury, In: Rayegani, S.M. Editor, Basic Principles of Peripheral Nerve Disorders, Rijeka, InTech d.o.o., 31-46.
    [3] Takaku S, Yanagisawa H, Watabe K, et al. (2013) GDNF promotes neurite outgrowth and upregulates galectin-1 through the RET/PI3K signaling in cultured adult rat dorsal root ganglion neurons. Neurochem Int 62: 330-339. doi: 10.1016/j.neuint.2013.01.008
    [4] Tsukamoto M, Sango K, Niimi N, et al. (2015) Upregulation of galectin-3 in immortalized Schwann cells IFRS1 under diabetic conditions. Neurosci Res 92: 80-85. doi: 10.1016/j.neures.2014.11.008
    [5] Delacour D, Koch A, Jacob R (2009) The role of galectins in protein trafficking. Traffic 10: 1405-1413 doi: 10.1111/j.1600-0854.2009.00960.x
    [6] Tracey BM, Feizi T, Abbott WM, et al. (1992) Subunit molecular mass assignment of 14,654 Da to the soluble beta-galactoside-binding lectin from bovine heart muscle and demonstration of intramolecular disulfide bonding associated with oxidative inactivation. J Biol Chem 267: 10342-10347.
    [7] Horie H, Inagaki Y, Sohma Y, et al. (1999) Galectin-1 regulates initial axonal growth in peripheral nerves after axotomy. J Neurosci 19: 9964-9974.
    [8] Inagaki Y, Sohma Y, Horie H, et al. (2000) Oxidized galectin-1 promotes axonal regeneration in peripheral nerves but does not possess lectin properties. Eur J Biochem 267: 2955-2964. doi: 10.1046/j.1432-1033.2000.01311.x
    [9] Kadoya T, Horie H (2005) Structural and functional studies of galectin-1: a novel axonal regeneration-promoting activity for oxidized galectin-1. Curr Drug Targets 6: 375-383. doi: 10.2174/1389450054022007
    [10] Camby I, Le Mercier M, Lefranc F, et al. (2006) Galectin-1: a small protein with major functions. Glycobiology 16: 137R-157R.
    [11] Plachta N, Annaheim C, Bissière S, et al. (2007) Identification of a lectin causing the degeneration of neuronal processes using engineered embryonic stem cells. Nature Neurosci 10: 712-719. doi: 10.1038/nn1897
    [12] Pesheva P, Kuklinski S, Schmitz B, et al. (1998) Galectin-3 promotes neural cell adhesion and neurite growth. J Neurosci Res 154: 639-654.
    [13] Chen H-L, Liao F, Lin T-N, et al. (2014) Chapter 24: Galectins and neuroinflammation, In: Yu, R.K. & Schengrund C.-L. Editors, Glycobiology of the Nervous System, Advances in Neurobiology 9, New York, Springer Science+Business Media, 517-542.
    [14] Regan LJ, Dodd J, Barondes SH, et al. (1986) Selective expression of endogenous lactose-binding lectins and lactoseries glycoconjugates in subsets of rat sensory neurons. Proc Natl Acad Sci U S A 83: 2248-2252. doi: 10.1073/pnas.83.7.2248
    [15] Fukaya K, Hasegawa M, Mashitani T, et al. (2003) Oxidized galectin-1 stimulates the migration of Schwann cells from both proximal and distal stumps of transected nerves and promotes axonal regeneration after peripheral nerve injury. J Neuropathol Exp Neurol 62: 162-172.
    [16] Akazawa C, Nakamura Y, Sango K, et al. (2004) Distribution of the galectin-1 mRNA in the rat nervous system: its transient upregulation in rat facial motor neurons after facial nerve axotomy. Neuroscience 125: 171-178. doi: 10.1016/j.neuroscience.2004.01.034
    [17] Park MJ, Chung K (1999) Endogenous lectin (RL-29) expression of the autonomic preganglionic neurons in the rat spinal cord. Anat Rec 254: 53-60.
    [18] Salt TE, Hill RG (1983) Neurotransmitter candidates of somatosensory primary afferent fibers. Neuroscience 10: 1083-1103. doi: 10.1016/0306-4522(83)90101-X
    [19] Sango K, Tokashiki A, Ajiki K, et al. (2004) Synthesis, localization and externalization of galectin-1 in mature dorsal root ganglion neurons and Schwann cells. Eur J Neurosci 19: 55-64. doi: 10.1046/j.1460-9568.2003.03102.x
    [20] McGraw J, Gaudet AD, Oschipok LW, et al. (2005) Altered primary afferent anatomy and reduced thermal sensitivity in mice lacking galectin-1. Pain 114: 7-18. doi: 10.1016/j.pain.2004.10.009
    [21] Takasaki I, Taniguchi K, Komatsu F, et al. (2012) Contribution of spinal galectin-3 to acute herpetic allodynia in mice. Pain 153: 585-592. doi: 10.1016/j.pain.2011.11.022
    [22] Molliver DC, Wright DE, Leitner ML, et al. (1997) IB4-binding DRG neurons switch from NGF to GDNF dependence in early postnatal life. Neuron 19: 849-861. doi: 10.1016/S0896-6273(00)80966-6
    [23] Ernsberger U (2009) Role of neurotrophin signalling in the differentiation of neurons from dorsal root ganglia and sympathetic ganglia. Cell Tissue Res 336: 349-384. doi: 10.1007/s00441-009-0784-z
    [24] Imbe H, Okamoto K, Kadoya T, et al. (2003) Galectin-1 is involved in the potentiation of neuropathic pain in the dorsal horn. Brain Res 993: 72-83. doi: 10.1016/j.brainres.2003.08.064
    [25] McGraw J, Gaudet AD, Oschipok LW, et al. (2005) Regulation of neuronal and glial galectin-1 expression by peripheral and central axotomy of rat primary afferent neurons. Exp Neurol 195: 103-114. doi: 10.1016/j.expneurol.2005.04.004
    [26] McGraw J, Oschipok LW, Liu J, et al. (2004) Galectin-1 expression correlates with the regenerative potential of rubrospinal and spinal motoneurons. Neuroscience 128: 713-719. doi: 10.1016/j.neuroscience.2004.06.075
    [27] Reichert F, Saada A, Rotshenker S (1994) Peripheral nerve injury induces Schwann cells to express two macrophage phenotypes: phagocytosis and the galactose-specific lectin MAC-2. J Neurosci 14: 3231-3245.
    [28] Mietto BS, Mostacada K, Martinez AM (2015) Neurotrauma and inflammation: CNS and PNS responses. Mediat Inflamm 2015: 251204.
    [29] Dussor G, Koerber HR, Oaklander AL, et al. (2009) Nucleotide signaling and cutaneous mechanisms of pain transduction. Brain Res Rev 60: 24-35. doi: 10.1016/j.brainresrev.2008.12.013
    [30] Carmillo P, Dagø L, Day ES, et al. (2005) Glial cell line-derived neurotrophic factor (GDNF) receptor a-1 (GFR a1) is highly selective for GDNF versus artemin. Biochemistry 44: 2545-2554. doi: 10.1021/bi049247p
    [31] Sango K, Yanagisawa H, Takaku S, et al. (2011) Immortalized adult rodent Schwann cells as in vitro models to study diabetic neuropathy. Exp Diabetes Res 2011:374943.
    [32] Scheib J, Höke A (2013) Advances in peripheral nerve regeneration. Nat Rev Neurol 9: 668-676. doi: 10.1038/nrneurol.2013.227
    [33] Outenreath RL, Jones AL (1992) Influence of an endogenous lectin substrate on cultured dorsal root ganglion cells. J Neurocytol 21: 788-795. doi: 10.1007/BF01237904
    [34] Mahanthappa NK, Cooper DN, Barondes SH, et al. (1994) Rat olfactory neurons can utilize the endogenous lectin, L-14, in a novel adhesion mechanism. Development 120: 1373-1384.
    [35] Puche AC, Poirier F, Hair M, et al. (1996) Role of galectin-1 in the developing mouse olfactory system. Dev Biol 179: 274-287. doi: 10.1006/dbio.1996.0257
    [36] Miura T, Takahashi M, Horie H, et al. (2004) Galectin-1b, a natural monomeric form of galectin-1 lacking its six amino-terminal residues promotes axonal regeneration but not cell death. Cell Death Differ 11: 1076-1083. doi: 10.1038/sj.cdd.4401462
    [37] Horie H, Kadoya T, Hikawa N, et al. (2004) Oxidized galectin-1 stimulates macrophages to promote axonal regeneration in peripheral nerves after axotomy. J Neurosci 24: 1873-1880.
    [38] Echigo Y, Sugiki H, Koizumi Y, et al. (2010) Activation of RAW264.7 macrophages by oxidized galectin-1. Immunol Lett 131: 19-23.
    [39] Kogawa Y, Nakajima K, Sasaguri K, et al. (2011) Oxidized galectin-1 reduces lipopolysaccharide-induced increase of proinflammatory cytokine mRNA in cultured macrophages. Clin Cosmet Investig Dent 19: 1-8.
    [40] Gaudet AD, Leung M, Poirier F, et al. (2009) A role for galectin-1 in the immune response to peripheral nerve injury. Exp Neurol 220: 320-327. doi: 10.1016/j.expneurol.2009.09.007
    [41] Gaudet AD, Sweet DR, Polinski NK, et al. (2015) Galectin-1 in injured rat spinal cord: implications for macrophage phagocytosis and neural repair. Mol Cell Neurosci 64: 84-94. doi: 10.1016/j.mcn.2014.12.006
    [42] Narciso MS, Mietto Bde S, Marques SA, et al. (2009) Sciatic nerve regeneration is accelerated in galectin-3 knockout mice. Exp Neurol 217: 7-15. doi: 10.1016/j.expneurol.2009.01.008
    [43] Mietto BS, Jurgensen S, Alves L, et al. (2013) Lack of galectin-3 speeds Wallerian degeneration by altering TLR and pro-inflammatory cytokine expressions in injured sciatic nerve. Eur J Neurosci 37: 1682-1690. doi: 10.1111/ejn.12161
    [44] Rotshenker S (2009) The role of Galectin-3/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease. J Mol Neurosci 39: 99-103. doi: 10.1007/s12031-009-9186-7
    [45] Gustavsson P, Linsmeier CE, Leffler H, et al. (2007) Galectin-3 inhibits Schwann cell proliferation in cultured sciatic nerve. Neuroreport 18: 669-673. doi: 10.1097/WNR.0b013e3280bef97b
    [46] Tucker BA, Rahimtula M, Mearow KM (2006) Laminin and growth factor receptor activation stimulates differential growth responses in subpopulations of adult DRG neurons. Eur J Neurosci 24: 676-690. doi: 10.1111/j.1460-9568.2006.04963.x
    [47] Wang W, Park JW, Wang JL, et al. (2006) Immunoprecipitation of spliceosomal RNAs by antisera to galectin-1 and galectin-3. Nucleic Acids Res 34: 5166-5174.
    [48] Yagihashi S, Mizukami H, Sugimoto K (2011) Mechanism of diabetic neuropathy: Where are we now and where to go? J Diabetes Investig 2: 18-32. doi: 10.1111/j.2040-1124.2010.00070.x
    [49] Mizisin AP (2014) Mechanisms of diabetic neuropathy: Schwann cells. Handb Clin Neurol 126: 401-428. doi: 10.1016/B978-0-444-53480-4.00029-1
    [50] Pugliese G, Iacobini C, Pesce CM, et al. (2015) Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 25: 136-150.
    [51] Pugliese G, Pricci F, Iacobini C, et al. (2001) Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 15: 2471-2479.
    [52] Kanda A, Noda K, Saito W, et al. (2015) Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep 5: 17946. doi: 10.1038/srep17946
    [53] Liu Y, Long L, Yuan F, et al. (2015) High glucose-induced Galectin-1 in human podocytes implicates the involvement of Galectin-1 in diabetic nephropathy. Cell Biol Int 39: 217-223. doi: 10.1002/cbin.10363
    [54] Mussche S, De Paepe B, Smet J, et al. (2012) Proteomic analysis in giant axonal neuropathy: new insights into disease mechanisms. Muscle Nerve 46: 246-256. doi: 10.1002/mus.23306
    [55] Franco PG, Pasquini LA, Pérez MJ, et al. (2015) Paving the way for adequate myelination: The contribution of galectin-3, transferrin and iron. FEBS Lett 589: 3388-3395. doi: 10.1016/j.febslet.2015.08.001
    [56] Peng W (2012) Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1. Immunol Lett 143: 146-151.
    [57] Bojarová P, Křen V (2016) Sugared biomaterial binding lectins: achievements and perspectives. Biomater Sci in press.
    [58] Kadoya T, Oyanagi K, Kawakami E, et al. (2005) Oxidized galectin-1 advances the functional recovery after peripheral nerve injury. Neurosci Lett 380: 284-288. doi: 10.1016/j.neulet.2005.01.054
    [59] Scott SA, Bugarcic A, Blanchard H (2009) Characterisation of oxidized recombinant human galectin-1. Protein Pept Lett 16: 1249-1255.
    [60] Guardia CM, Caramelo JJ, Trujillo M, et al. (2014) Structural basis of redox-dependent modulation of galectin-1 dynamics and function. Glycobiology 24: 428-441.
    [61] Lin YT, Chen JS, Wu MH, et al. (2015) Galectin-1 accelerates wound healing by regulating the neuropilin-1/Smad3/NOX4 pathway and ROS production in myofibroblasts. J Invest Dermatol 135: 258-268. doi: 10.1038/jid.2014.288
    [62] Pugliese G, Iacobini C, Pesce CM, et al. (2015) Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 25: 136-150.
  • Reader Comments
  • © 2016 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6441) PDF downloads(1574) Cited by(1)

Article outline

Figures and Tables

Figures(4)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog